Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD-L1 therapy in the advanced gastric cancer.
Advanced Gastric Cancer
PROCEDURE: Fecal Microbiota Transplantation Capsules|PROCEDURE: Placebo
Objective response rate (ORR), ORR is defined as the percentage of subjects who had a complete response (CR) or partial response (PR), as defined by ir-RECIST v1.1, and is based on the best response obtained., up to 6 months|Rate of Disease Control, Rate of Disease Control is defined as the percentage of subjects who had a complete response (CR), partial response (PR), or stable disease (SD), as defined by ir-RECIST v1.1., up to 6 months
Progression-free Survival (PFS), The median length of time from initiation of study drug(s) disease progression as defined by RECIST v1.1, or death. Progressive Disease (PD): ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression., up to 2 years|Overall Survival (OS), The length of time (in days) from study intervention that participants remain alive., up to 2 years|Incidence of Adverse Events Related to Treatment, All adverse events and their relationships to study drugs and procedures will be recorded，to assess overall safety, feasibility and tolerability of treatment., up to 6 months|Change in the intestinal microbiome community, Mean change from baseline of bacterial species compared with 6 months post fecal microbiota transplantation (FMT)., up to 6 months|Quality of life based on the questionnaire, The EQ-5D-5L questionnaire will be used to assess the quality of life of the participants., up to 2 years|Quality of life based on the questionnaire, The FACT-GA questionnaire will be used to assess the quality of life of the participants., up to 2 years|Change in the immunity, Mean change from baseline of immune cells compared with 6 months post fecal microbiota transplantation (FMT)., up to 6 months
Marker of nutritional status, Hemoglobin is a measure of the nutritional status and are seen as markers for the catabolic state of cachectic cancer patients., up to 2 years|Marker of nutritional status, Creatinin is a measure of the nutritional status and is seen as markers for the catabolic state of cachectic cancer patients., up to 2 years|Marker of nutritional status, Albumin is a measure of the nutritional status and is seen as markers for the catabolic state of cachectic cancer patients., up to 2 years|Body Weight, Body Weight Change. (kilograms), up to 2 years|Appetite, Appetite measured by FAACT, up to 2 years|Marker of nutritional status, C-reactief proteïne is a measure of the nutritional status and is seen as markers for the catabolic state of cachectic cancer patients., up to 2 years|Marker of nutritional status, Lactate dehydrogenase (LDH) is a measure of the nutritional status and is seen as markers for the catabolic state of cachectic cancer patients., up to 2 years
This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD1/PDL1 therapy in the advanced gastric cancer.